Columbus, Ohio – Clara D. Bloomfield, MD, Distinguished University Professor, cancer scholar and senior advisor to The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James), has received the 2017 Robert A. Kyle Award for Outstanding Clinician-Scientist.
The award is presented by the Mayo Clinic’s Division of Hematology to recognize outstanding contributions in the diagnosis and treatment of hematologic cancers, which include leukemias, lymphomas and multiple myeloma.
The award recognizes Bloomfield for more than three decades of research in the field of acute myeloid leukemia (AML). She has more than 600 published articles and is internationally renowned for her work in the cytogenetics of adult acute leukemia, for the molecular genetics of AML and for contributions to the treatment of AML, particularly in older patients.
She has made significant contributions to the World Health Organization’s classification of AML and to the European LeukemiaNet recommendations for diagnosis and management of AML, which guide the structure of clinical trials and help establish AML standards of care.
As part of receipt of the award, Bloomfield presented two talks: “Advances in Acute Leukemia: Believe What You See, Not What They Say,” and “Biologic Heterogeneity of AML: Implications for Prognosis and Treatment.”
Bloomfield, who also holds the William Greenville Pace III Endowed Chair in Cancer Research, served as director of Ohio State’s Comprehensive Cancer Center from 1997 to July 2003. She then became senior adviser to the OSUCCC – James and the charter member of Ohio State’s Cancer Scholars Program, which is designed to help recruit and retain senior cancer investigators of international stature.
Bloomfield earned her MD from the University of Chicago and completed training in internal medicine and medical oncology at the University of Minnesota, where she became a full professor in seven years. In 1989 she became professor of medicine and chief of the Division of Oncology at the State University of New York at Buffalo, as well as chair of the Division of Medicine at Roswell Park Cancer Institute.
The recipient of numerous major awards, in 2000, Bloomfield was elected to the Institute of Medicine of the National Academy of Sciences (currently the National Academy of Medicine) and in 201l she was elected to the American Academy of Arts and Sciences. At the OSUCCC – James, she is also a member of the Leukemia Research Program, and a professor of Internal Medicine.
About the OSUCCC – James
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 49 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs sponsored by the NCI. As the cancer program’s 308-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet® designation, the highest honor an organization can receive for quality patient care and professional nursing practice. At 21 floors with more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care.
Amanda Harper, director, Media Relations
Direct: 614-685-5420; central media office: 614-293-3737
Written by: Darrell E. Ward, associate director for Cancer Communications
614-293-3737, or Darrell.Ward@osumc.edu